Last updated date
ABOUT THIS STUDY
Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected
to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance
recommends a study in subjects with renal impairment when the drug is likely to be used in
patients with impaired renal function. Palbociclib is intended for chronic use in cancer
patients who may have some degree of impaired renal function.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Impairment
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Personally signed and dated informed consent document.
- Renal function calculated by the Cockcroft Gault equation: normal function (CLcr >=90 mL/min), mild: CLcr >=60 mL/min and <90 mL/min, moderate: CLcr >=30 mL/min and <60 mL/min, severe: CLcr <30 mL/min but not requiring hemodialysis.
- Subjects with normal renal function matched for age, weight, gender and race to subjects in impaired renal function groups.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Any condition possibly affecting drug absorption.
- Renal allograft recipients.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Renal ImpairmentA Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
NCT01419041
- Anaheim, California
- DeLand, Florida
- Saint Paul, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal ImpairmentStudy Of Palbociclib (PD-0332991) In Renal Impairment
NCT02085538
- DeLand, Florida
- Orlando, Florida
- Saint Paul, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal ImpairmentPharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
NCT01740362
- Orlando, Florida
- New Orleans, Louisiana
- New Orleans, Louisiana
- Minneapolis, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal ImpairmentA Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
NCT00785772
- Saijyo-shi, Ehime
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Of Palbociclib (PD-0332991) In Renal Impairment | |||
| Official Title ICMJE | A Phase 1, Open-label, Single Dose, Parallel-group Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Renal Function | |||
| Brief Summary | Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance recommends a study in subjects with renal impairment when the drug is likely to be used in patients with impaired renal function. Palbociclib is intended for chronic use in cancer patients who may have some degree of impaired renal function. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 1 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Basic Science | |||
| Condition ICMJE | Renal Impairment | |||
| Intervention ICMJE | Drug: palbociclib
palbociclib 125 mg oral capsule with food once | |||
| Study Arms ICMJE |
| |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 31 | |||
| Original Estimated Enrollment ICMJE | 28 | |||
| Actual Study Completion Date ICMJE | May 2016 | |||
| Actual Primary Completion Date | May 2016 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | Yes | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT02085538 | |||
| Other Study ID Numbers ICMJE | A5481014 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | April 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||